21 stocks hit 52-week low in a week when Sensex scaled record high
Potential risks highlighted by Macquarie Capital Securities for Paytms business from the foray by Reliance Industries into financial, prompted investors to dump shares of One97 Communications, which has already been one of the worst performers in 2022 so far.
Ahead of Market: 10 things that will decide D-St action on Wednesday
“Nifty started flat following global peers and moved up higher by the end of the session. On the higher end, it moved back above 18,200. A bullish harami pattern on the daily chart suggests a recovery in the term. The trend looks sideways to positive. Going forward, 18,200 may provide immediate support below which the index may drift down towards 18,100. On the higher end, resistance is visible at 18,300/18,450,” Rupak De, Senior Technical Analyst at LKP Securities, said.
Shilpa Medicare Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 3384.41 Crore) operating in Pharmaceuticals sector.
Gensol Engineering: The company will be in focus as it has approved the acquisition of a majority stake in Gensol Electric Vehicles, which will further acquire technical and business know-how, patents, trademark and brand name related to electric vehicles from th......read more
Mindtree, Tata Metaliks, Gujarat Hotels, International Travel House, Premier Polyfilm, Ramasigns Industries, and Jupiter Industries & Leasing will be in focus ahead of quarterly earnings on July 13.
Stocks in News
HCL Technologies: The IT services company clock......read more
La Tim Metal & Industries Limited board approves stock split
RITES, IT-Delhi sign MoU on road design & safety works
Seamec: Along With Consortium Partner Entered Understanding With Larsen & Toubro || Total Combined Value Of Contract To Consortium Is $1......read more
Mylab partners with Shilpa Biologicals to enter vaccines & therapeutics segment
Adar Poonawalla-backed Mylab plans to develop world-class diagnostics, vaccines and therapeutics to augment its presence in the healthcare market. The company will leverage the technical expertise of Shilpa Biologicals in development and manufacture of biopharmaceuticals through its facility at Dharwad.
Zydus Cadila to get clarity on ZyCoV-D Covid vaccine pricing in 1-2 weeks: MD Sharvil Patel
On Sunday, news wire PTI reported, citing government sources, that the company had agreed to bring down the price of ZyCov-D to ₹265 a dose following negotiations with the government but that a final deal had not yet been reached.
India's Shilpa Medicare to make Cadila's COVID-19 vaccine
The country's health authorities had given emergency approval in August for Cadila's vaccine, the world's first COVID-19 DNA shot, in adults and children aged 12 years and above.
#SHILPAMED : The company approved the transfer of API business consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka by way of slump sale to a wholly owned subsidiary of the company.
Sensex gains in early trade, Nifty above 15,750; Ashoka Buildcon rises 4%, Shilpa Medicare 3%
The S&P BSE Sensex index rose as much as 344 points to touch 52,716.83 in the first few minutes of trade, and the broader NSE Nifty 50 benchmark climbed to as high as 15,796.25, up 104 points from its previous close.
Reliance Industries: The company has invested Rs 1,00,000 in cash in 10,000 equity shares of Rs 10 each of 'Reliance New Energy Solar' (RNESL), a newly incorporated wholly owned subsidiary. RNESL is incorporated to undertake activities relating to solar energy. RNE......read more